- Previous close
1.5700 - Open
1.5900 - Bid --
- Ask --
- Day's range
1.5100 - 1.6491 - 52-week range
1.2000 - 10.4000 - Volume
9,991 - Avg. Volume
87,449 - Market cap (intra-day)
10.098M - Beta (5Y monthly) 1.08
- PE ratio (TTM)
-- - EPS (TTM)
-4.4600 - Earnings date Mar 5, 2025 - Mar 9, 2025
- Forward dividend & yield --
- Ex-dividend date --
- 1y target est
8.12
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, gastrointestinal inflammatory related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
www.evogene.comRecent news: EVGN
View morePerformance overview: EVGN
Trailing total returns as of 1/30/2025, which may include dividends or other distributions. Benchmark is .
YTD return
1-year return
3-year return
5-year return
Compare to: EVGN
Select to analyse similar companies using key performance metrics; select up to four stocks.
Statistics: EVGN
View moreValuation measures
Market cap
9.89M
Enterprise value
944.22k
Trailing P/E
0.32
Forward P/E
--
PEG ratio (5-yr expected)
--
Price/sales (ttm)
1.09
Price/book (mrq)
4.71
Enterprise value/revenue
0.13
Enterprise value/EBITDA
--
Financial highlights
Profitability and income statement
Profit margin
-210.26%
Return on assets (ttm)
-28.46%
Return on equity (ttm)
-82.37%
Revenue (ttm)
9.45M
Net income avi to common (ttm)
-19.87M
Diluted EPS (ttm)
-4.4600
Balance sheet and cash flow
Total cash (mrq)
20.91M
Total debt/equity (mrq)
4.06%
Levered free cash flow (ttm)
-2.42M